scispace - formally typeset
M

Monkol Lek

Researcher at Yale University

Publications -  22
Citations -  6437

Monkol Lek is an academic researcher from Yale University. The author has contributed to research in topics: Exome & Genome. The author has an hindex of 8, co-authored 22 publications receiving 3334 citations. Previous affiliations of Monkol Lek include Broad Institute.

Papers
More filters
Journal ArticleDOI

The mutational constraint spectrum quantified from variation in 141,456 humans

TL;DR: A catalogue of predicted loss-of-function variants in 125,748 whole-exome and 15,708 whole-genome sequencing datasets from the Genome Aggregation Database (gnomAD) reveals the spectrum of mutational constraints that affect these human protein-coding genes.
Posted ContentDOI

Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes

Konrad J. Karczewski, +95 more
- 30 Jan 2019 - 
TL;DR: Using an improved human mutation rate model, human protein-coding genes are classified along a spectrum representing tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve gene discovery power for both common and rare diseases.
Journal ArticleDOI

Author Correction: The mutational constraint spectrum quantified from variation in 141,456 humans

Konrad J. Karczewski, +95 more
- 03 Feb 2021 - 
Journal ArticleDOI

The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution

Deanne Taylor, +82 more
- 08 Apr 2019 - 
TL;DR: The case for a Pediatric Cell Atlas as part of the Human Cell Atlas consortium to provide single-cell profiles and spatial characterization of gene expression across human tissues and organs is discussed.
Journal ArticleDOI

Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases.

TL;DR: The increasing size of aggregated population variant databases will allow for robust and reproducible prevalence estimates of recessive disease, which is critical for the strategic design and prioritization of clinical trials.